Skip to main content

Hemophagocytic Lymphohistiocytosis clinical trials at UCLA

1 in progress, 0 open to eligible people

Showing trials for
  • ELA026 in Participants with Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

    Sorry, in progress, not accepting new patients

    Hemophagocytic lymphohistiocytosis is a rare, aggressive and life-threatening syndrome of excessive immune activation. Secondary hemophagocytic lymphohistiocytosis (sHLH) is the most common form of this disease and is typically associated with several other clinical conditions (eg, malignancy associated HLH (mHLH), infection, or autoimmune disease). ELA026 is a fully human immunoglobulin G1 (IgG1) signal regulatory protein (SIRP)-directed monoclonal antibody designed to deplete the myeloid and T cells driving the inflammation. The purpose of this study is to assess the safety, efficacy pharmacokinetics and pharmacodynamics of ELA026 in participants with sHLH.

    Los Angeles, California and other locations

Last updated: